Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07054684 · ClinicalTrials.gov registry record · Phase 1

Study of BHV-1400 in IgA Nephropathy

A Phase 1 study of IgA Nephropathy, sponsored by Biohaven Therapeutics.

Recruiting
Registry status
Phase 1
Development phase
20
Enrollment target
12
Study locations

NCT07054684: Recruiting Phase 1 study of IgA Nephropathy, sponsored by Biohaven Therapeutics.

NCT07054684 is a Phase 1 study of IgA Nephropathy that is actively recruiting participants, run by Biohaven Therapeutics. The registered enrollment target is 20 participants, below the 165-participant average among 10 other IgA Nephropathy trials with a reported enrollment target (88% lower). The trial reports 12 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07054684, a Phase 1 study of IgA Nephropathy, is actively recruiting participants, sponsored by Biohaven Therapeutics.

RECRUITING
Registry status
Phase 1
Development phase
20 participants
Enrollment target
12
Study locations

Study Summary

The purpose of this study is to determine if BHV-1400 is a safe and tolerable treatment in participants with IgA Nephropathy (IgAN).

Primary Outcome

To assess the safety and tolerability of BHV-1400. This objective will be measured by assessing the number of unique subjects with SAEs, moderate or severe AEs, AEs leading to discontinuation or deaths

Conditions Studied

IgA Nephropathy

Interventions

  • DRUG BHV-1400

Study Locations (12)

Florida

  • Site-003 - Miami Lakes
  • Site-011 - Miami Lakes
  • Site-013 - Orlando
  • Site-005 - Pembroke Pines

Connecticut

  • Site-001 - Farmington

Georgia

  • Site-008 - Lawrenceville

Illinois

  • Site-009 - Hinsdale

Indiana

  • Site-012 - Indianapolis

Missouri

  • Site-006 - Chesterfield

South Dakota

  • Site-002 - Dakota Dunes

Texas

  • Site-004 - Houston

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2025-07-30
Est. Completion 2027-07
Phase Phase 1
Biohaven Therapeutics

16 total trials

What NCT07054684 shows while recruiting

NCT07054684 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 165-participant average among 10 other IgA Nephropathy trials with a reported enrollment target (88% lower).

The record links to 1 condition, with IgA Nephropathy appearing as the primary indexed condition, and to 1 intervention - of which BHV-1400 is the first listed.

NCT07054684 lists 12 locations in 9 states (Florida, Connecticut, Georgia).

Frequently Asked Questions

What is clinical trial NCT07054684 about?

NCT07054684 is a clinical study titled "Study of BHV-1400 in IgA Nephropathy". The purpose of this study is to determine if BHV-1400 is a safe and tolerable treatment in participants with IgA Nephropathy (IgAN).

What is the current status of trial NCT07054684?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2025-07-30. Estimated completion is 2027-07.

What conditions does trial NCT07054684 study?

This clinical trial studies the following conditions: IgA Nephropathy.

What interventions are being tested in trial NCT07054684?

The interventions under investigation include: BHV-1400 (DRUG).

Who is sponsoring clinical trial NCT07054684?

This trial is sponsored by Biohaven Therapeutics, which has 16 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07054684 being conducted?

This trial has 12 study locations across Connecticut, Florida, Georgia, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for IgA Nephropathy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07054684's enrollment target sits among peer trials

20 11th of 10 the lowest of 10 other IgA Nephropathy trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other IgA Nephropathy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00573339 · 20 participants

    Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing

  • NCT00692939 · 20 participants · Phase 1

    Autologous Stem Cell Transplantation for Crohn's Disease

  • NCT00967785 · 20 participants · Phase 1

    A Phase I Study of Mozobil in the Treatment of Patients With WHIMS

  • NCT01406691 · 20 participants · Phase 4

    Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT07054684

Source: ClinicalTrials.gov NCT07054684, the US trial registry maintained by the National Library of Medicine. NCT07054684 (small enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.